Strategic partnership Potential license and co-development discussions with larger female health and infection control players (e.g., Daré Bioscience collaboration) to scale commercialization of novel antimicrobial GML and related anti-infective platforms.

Clinical-stage leverage Target opportunities with contract research organizations, hospital systems, and specialty clinics seeking innovative anti-infectives for hospital acquired infections and women's health, aligning clinical trial progress with pilot deployments.

Platform expansion Cross-market appeal in human and animal health suggests selling partnerships with veterinary and zoonotic health players, leveraging broad-spectrum activity against bacteria, fungi, and viruses for integrated infection prevention portfolios.

IP and protection Emphasize patent-protected, naturally derived anti-infectives to attract investors and strategic buyers seeking differentiated IP assets with lower resistance potential and clear regulatory and safety advantages.

Growth signals Position the company’s growth-stage trajectory, small team scalability, and existing funding as a compelling case for early-stage funds and strategic acquirers looking to accelerate entry into the superbug and women's health markets.